CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Antihistamines and Birth Defects: A Systematic Review of the Literature
-
Oct 11 2014
-
-
Source: Expert Opin Drug Saf. 13(12):1667-1698.
[PDF-525.33 KB]
Details:
-
Alternative Title:Expert Opin Drug Saf
-
Personal Author:
-
Description:Introduction
Approximately 10-15% of women reportedly take an antihistamine during pregnancy for the relief of nausea and vomiting, allergy and asthma symptoms, or indigestion. Antihistamines include histamine H1-receptor and H2-receptor antagonists.
Areas covered
This is a systematic evaluation of the peer-reviewed epidemiologic literature published through February 2014 on the association between prenatal exposure to antihistamines and birth defects. Papers addressing histamine H1- or H2-receptor antagonists are included. Papers addressing pyridoxine plus doxylamine (Bendectin in the United States, Debendox in the United Kingdom, Diclectin in Canada, Lenotan and Merbental in other countries) prior to the year 2001 were excluded post-hoc because of several previously published meta-analyses and commentaries on this medication.
Expert opinion
The literature on the safety of antihistamine use during pregnancy with respect to birth defects is generally reassuring though the positive findings from a few large studies warrant corroboration in other populations. The findings in the literature are considered in light of three critical methodological issues: (1) selection of appropriate study population; (2) ascertainment of antihistamine exposures; and (3) ascertainment of birth defects outcomes. Selected antihistamines have been very well-studied (e.g. loratadine); others, especially H2- receptor antagonists, require additional study before an assessment of safety with respect to birth defects risk could be made.
-
Subjects:
-
Source:
-
Pubmed ID:25307228
-
Pubmed Central ID:PMC4474179
-
Document Type:
-
Funding:
-
Volume:13
-
Issue:12
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
